Model Medicines is an AI/ML drug discovery company that leverages a historical compendium of drug development data and a drug- and disease-agnostic discovery platform to create Phase II/III-ready drug candidates. The company has developed a pipeline of patent-pending therapeutics across oncology, infectious diseases, gastric disorders, neurological disorders, and weight disorders. It recently used its platform to discover MDL-001, a once-daily oral infectious disease candidate moved from concept to IND-enabling studies in less than 12 months and at a fraction of traditional development costs. Model Medicines also identified and validated over 30 in vitro disease-model drug candidates for novel infectious disease targets discovered by Sanford Burnham Prebys and virologist Dr. Sumit Chanda. Following the $4.1M financing, the company plans to bolster its internal therapeutic pipeline, expand R&D to broaden platform functionality and enhance discovery efficacy, and recruit scientific, clinical, technical, and business leaders. The company is led by CEO Daniel Haders II, Ph.D., and is based in San Diego, CA.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2021